Core Viewpoint - Vanda Pharmaceuticals calls for stronger FDA action to accelerate the transition from animal testing to human-relevant methods in drug development, expressing concerns over the FDA's draft guidance released on March 18, 2026 [1][2]. Summary by Sections FDA Draft Guidance - The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs) to modernize nonclinical testing and reduce reliance on traditional animal models [2]. - Vanda acknowledges the FDA's commitment to improving human predictivity and ethical standards but believes the draft lacks the necessary reforms for effective implementation [2]. Vanda's Advocacy - Vanda has a history of advocating for science-driven changes, including legal challenges against prolonged animal studies that lack scientific justification [3]. - The company emphasizes the ethical need to minimize animal suffering while advancing predictive human-relevant methods [3]. Key Shortcomings in the Draft - The draft guidance is criticized for vague validation requirements, insufficient transparency, and a lack of concrete examples of accepted NAMs [5]. - There are no specific NAMs mentioned that the FDA currently accepts to replace required animal tests, which creates uncertainty for developers [5]. Recommendations for FDA - Vanda urges the FDA to collaborate with industry innovators and animal welfare groups to refine the guidance [5]. - The company calls for clear pathways for regulatory acceptance that prioritize human relevance and evidence-based confidence [5]. - Vanda suggests incorporating robust citations and specific examples of validated NAMs to enhance the guidance [5][6].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $23.7 million, above the midpoint of guidance but down from $24.6 million in Q4 2024 [12] - Gross margin improved to 59.77%, up 260 basis points from 57.1% in Q4 2024, marking the highest gross margin in seven quarters [12][13] - Adjusted EBITDA for Q4 increased by 27% year-over-year to $3.8 million [12][14] - Full year revenue decreased to $86.6 million from $94.1 million, primarily due to tariffs and delayed NIH funding [15] - Full year adjusted EBITDA increased by 12.5% to $8.1 million from $7.2 million in 2024 [15] Business Line Data and Key Metrics Changes - The company is transitioning to higher margin product lines, with approximately 55% of revenue now recurring [9] - Key products like BTX and Mesh MEA are expected to grow in double digits in 2026 [28] Market Data and Key Metrics Changes - Q4 revenues in the Americas were down 2% year-over-year, while Europe saw a 12% decline due to lower academic sales [16][17] - In China and the Asia Pacific, Q4 revenues increased by 10% year-over-year, driven by growth in preclinical distribution [17] Company Strategy and Development Direction - The company is evolving from a traditional life science tools provider to a leader in translational science, focusing on bridging in vivo and in vitro research [8] - Four strategic priorities include leading the translational science bridge, accelerating high margin innovation, expanding consumables and recurring revenue, and operational excellence [9] Management Comments on Operating Environment and Future Outlook - Management anticipates low single-digit revenue growth and high single-digit Adjusted EBITDA growth for 2026, driven by higher margin NPI growth [10] - The company is well-positioned to manage volatility due to its diversified geographic footprint and improved cost structure [10] Other Important Information - The company completed a comprehensive refinancing that extended debt maturity to 2029 and reduced annual debt service by $3 million [4][19] - The company ended the year with the highest backlog in over two years, indicating positive momentum [35] Q&A Session Summary Question: How quickly do you think NIH approval will improve the academic environment? - Management expects a positive impact towards the end of Q1 and into Q2 as grant submissions are approved [26][27] Question: What is the expected growth for key products like BTX and Mesh MEA in 2026? - Both products are expected to grow in double digits this year [28] Question: Can you provide insights on the Asia Pacific revenue and expectations for 2026? - Management sees improvement in Asia Pacific revenue and expects to return to a normal cadence, barring any new tariff issues [34] Question: How is the pharmaceutical biotech CRO side of the business performing? - The pharma and biotech segment is up year-to-date, and management expects this trend to continue [38]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $23.7 million, above the midpoint of guidance but down from $24.6 million in Q4 2024 [12] - Gross margin improved to 59.77%, up 260 basis points from 57.1% in Q4 2024, marking the highest gross margin in the last seven quarters [12][13] - Adjusted EBITDA for Q4 2025 was $3.8 million, reflecting a 27% year-over-year growth [6][13] - Full year revenue for 2025 was $86.6 million, down from $94.1 million in 2024, primarily due to tariffs and delayed NIH funding [14] - Full year adjusted EBITDA increased 12.5% to $8.1 million from $7.2 million in 2024 [15] Business Line Data and Key Metrics Changes - The Americas saw a 2% year-over-year decline in Q4 revenue, driven by lower pharma and academic sales [16] - European revenues decreased by 12% year-over-year in Q4, attributed to lower academic sales [17] - In China and the Asia Pacific, Q4 revenues increased by 10% year-over-year, supported by growth in preclinical distribution [17] Market Data and Key Metrics Changes - NIH revenue constitutes about 20% of U.S. revenue, with expectations for improvement in orders following recent approvals [27] - The company experienced a backlog at the highest level in over two years, indicating positive demand trends [36] Company Strategy and Development Direction - The company is transitioning from a traditional life science tools provider to a leader in translational science, focusing on bridging in vivo and in vitro research [8] - Key strategic priorities include leading the translational science bridge, accelerating high-margin innovation, expanding consumables and recurring revenue, and maintaining operational excellence [9][10] - The company aims for low single-digit revenue growth and high single-digit Adjusted EBITDA growth in 2026, driven by higher margin new product innovations [10][22] Management Comments on Operating Environment and Future Outlook - The life science industry is undergoing a fundamental shift, with drug development remaining inefficient [7] - The company is well-positioned to manage volatility due to its diversified geographic footprint and improved cost structure [10] - 2025 was characterized as a strategic reset, with 2026 expected to be a year of growth in both top and bottom lines [10][23] Other Important Information - The company completed a comprehensive refinancing that extended debt maturity to 2029 and reduced annual debt service by $3 million [4][19] - The company has reinstated bonuses and merit-based compensation for employees in 2026, which had been suspended in 2025 [21] Q&A Session Summary Question: How quickly do you think NIH approval will improve the academic environment? - Management expects to see a positive impact towards the end of Q1 and into Q2 following NIH approval [26][27] Question: What is the expected growth for key products like BTX and Mesh MEA in 2026? - Both products are expected to grow in double digits this year [28] Question: What are the expectations for the Asia Pacific revenue turnaround? - Management noted improvement in orders and expects a return to normal cadence in Asia, barring any new tariff issues [35] Question: How is the pharmaceutical biotech CRO side of the business performing? - The pharma and biotech segment is up year-to-date, and management expects this trend to continue [39]

Core Insights - Harvard Bioscience, Inc. reported financial results for Q4 and the full year 2025, highlighting a transition towards becoming a leader in translational science and a focus on New Approach Methodologies (NAMs) [2][9] Financial Performance - Q4 2025 revenues were $23.7 million, a decrease from $24.6 million in Q4 2024, while gross margin improved to 59.7% from 57.1% year-over-year due to cost containment and a favorable product mix [3] - The net loss for Q4 2025 was ($2.8) million compared to a net income of $18 thousand in Q4 2024, with adjusted EBITDA increasing to $3.8 million from $3.0 million [4] - For the full year 2025, revenues totaled $86.6 million, down from $94.1 million in 2024, attributed to a challenging global market and reduced spending by customers [5] - The gross margin for the year was 57.7%, slightly down from 58.2% in 2024, impacted by fixed manufacturing overhead costs [5] - The net loss for 2025 was ($56.7) million, significantly higher than the ($12.4) million loss in 2024, primarily due to a goodwill impairment of $48.0 million [6] Operational Developments - The company has streamlined its operating model and strengthened its balance sheet throughout 2025, positioning itself for future growth [2] - Mark Frost has been appointed as the permanent CFO, expressing optimism about the company's future and engagement with stakeholders [2] Future Outlook - Guidance for 2026 anticipates revenue growth driven by new product innovations in translational science, supported by a stabilized NIH funding environment and reduced tariff disruptions [11] - The company expects revenue growth between 2% and 4%, with adjusted gross margins between 58% and 60% and adjusted EBITDA growth between 6% and 10% [16]

Core Insights - VivoSim Labs, Inc. has appointed Dr. Arumugham Raghunathan as Vice President of Global Sales to enhance commercial growth and partnerships in the biopharma sector, particularly focusing on liver and gastrointestinal toxicity solutions [1][2][3] Company Overview - VivoSim Labs, Inc. specializes in next-generation New Approach Methodologies (NAMs) for preclinical safety, utilizing three-dimensional human tissue models for liver and intestinal toxicology [7] - The company is based in San Diego, California, and aims to accelerate the adoption of human tissue models following regulatory changes favoring non-animal testing methods [7] Leadership and Strategy - Dr. Raghunathan is recognized for his ability to build consultative relationships and guide clients from pilot studies to large-scale deployments, particularly in safety assessment and decision-making [2][3] - Under his leadership, VivoSim will focus on enhancing customer engagement and delivering solutions that provide clearer insights into drug candidate toxicity, thereby improving decision-making processes [4][5] Market Demand and Services - There is a growing demand for human-relevant toxicity prediction tools, especially in the Boston area and along the East Coast, as drug development timelines shorten and modalities diversify [5] - VivoSim's services are designed to support various stakeholders, including biotech startups, large pharmaceutical companies, and academic institutions, by providing insights into liver and GI toxicity [6]

Financial Data and Key Metrics Changes - The company reported Q4 2025 revenue of $994.2 million, a 2.6% decline on an organic basis from the previous year, with full-year revenue of $4.02 billion, reflecting a 1.6% organic revenue decrease [17][19] - Non-GAAP earnings per share for Q4 were $2.39, a decrease of 10.2% from $2.66 in Q4 2024, while full-year earnings per share were nearly flat at $10.28 compared to $10.32 in 2024 [19][20] - The operating margin decreased by 100 basis points year-over-year to 18.1% in Q4, primarily due to lower revenue and higher costs [18][23] Business Segment Data and Key Metrics Changes - DSA revenue in Q4 was $591.6 million, a decrease of 3.3% on an organic basis, with a full-year decline of 2.6% [20][23] - RMS revenue in Q4 was $206.3 million, a decrease of 0.9% on an organic basis, while full-year RMS revenue increased by 1.2% [24][25] - Manufacturing solutions revenue for Q4 was $196.4 million, a decrease of 2.1% on an organic basis, with full-year revenue declining 1.6% [26][27] Market Data and Key Metrics Changes - The DSA net book-to-bill improved to 1.1 times in Q4, driven by small and mid-sized biotech clients, with net bookings of $665 million [9][22] - The biotech funding environment saw a record level of $28 billion in Q4, contributing to a steady increase in DSA net book-to-bill [8][9] Company Strategy and Development Direction - The company is focused on strategic acquisitions to strengthen its portfolio, including the acquisition of K.F. Cambodia and PathoQuest, aimed at enhancing operational efficiency and securing supply chains [10][12] - The company plans to continue evaluating additional M&A opportunities to support clients in drug development programs [13][14] - The transition in leadership to Birgit Girshick as the new CEO is expected to drive forward the company's strategic direction and operational excellence [30][34] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding favorable DSA demand trends continuing into 2026, anticipating a return to organic revenue growth in the second half of the year [9][37] - The company expects operating margin improvement in 2026, driven by the acquisition of K.F. Cambodia and cost-saving initiatives [35][39] - Management acknowledged challenges in the first quarter of 2026, including higher NHP sourcing costs and stock compensation expenses due to the CEO transition [54][42] Other Important Information - The company plans to generate at least $100 million in incremental cost savings in 2026, building on previous restructuring initiatives [41][58] - The anticipated Non-GAAP tax rate for 2026 is expected to decrease to 22%-23% from 24.6% in 2025, benefiting from favorable geographic mix and tax rate changes [56][57] Q&A Session Summary Question: Dynamics between RMS and DSA regarding NHPs - Management clarified that RMS volumes were impacted by timing, while DSA faced higher sourcing costs due to unexpected demand for NHP studies [63][65] Question: DSA cancellations and their impact - Management indicated that cancellations were within normal ranges and manageable due to a strong backlog [83][85] Question: Hiring needs in relation to DSA bookings - Management stated that they are in good shape regarding capacity and headcount, with careful alignment to demand [72][74] Question: Impact of AI on the business - Management emphasized that AI is viewed as an enabling technology rather than a disruptor, and they are embracing it strategically [76][78]

Charles River Laboratories (NYSE:CRL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsBirgit Girshick - EVP and COOCasey Woodring - VP, Equity ResearchDave Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorEric Coldwell - Managing DirectorJames Foster - Chair, President and CEOLuke Sergott - Director - Healthcare Equity ResearchMichael Knell - VP and Chief Financial OfficerMichael Ryskin - Managing DirectorTodd Spencer - VP of Investor RelationsConference Call P ...

Financial Data and Key Metrics Changes - The company reported revenue of $994.2 million in Q4 2025, a 2.6% decline on an organic basis from the previous year, with full-year revenue of $4.02 billion, reflecting a 1.6% organic revenue decrease [12][14] - Earnings per share were $2.39 in Q4 2025, a decrease of 10.2% from $2.66 in Q4 2024, while full-year earnings per share were nearly flat at $10.28 compared to $10.32 in 2024 [14] - The operating margin decreased by 100 basis points year-over-year to 18.1% in Q4, while the full-year operating margin declined by just 10 basis points to 19.8% [13][14] Business Segment Data and Key Metrics Changes - DSA revenue in Q4 was $591.6 million, a decrease of 3.3% on an organic basis, with a full-year decline of 2.6% [15] - RMS revenue in Q4 was $206.3 million, a decrease of 0.9% on an organic basis, while full-year RMS revenue increased by 1.2% [19] - Manufacturing solutions revenue was $196.4 million for Q4, a decrease of 2.1% on an organic basis, with full-year revenue declining by 1.6% [21][22] Market Data and Key Metrics Changes - The DSA net book-to-bill improved to 1.1 times in Q4, driven by small and mid-sized biotech clients, with a backlog of $1.86 billion at year-end [6][17] - The biotech funding environment saw a record level of $28 billion in Q4, contributing to a steady increase in DSA net bookings [6][12] - Sales to global biopharma clients rebounded in Q4, while small and mid-sized biotech clients experienced a modest decline [12][13] Company Strategy and Development Direction - The company is focused on strategic acquisitions to strengthen its portfolio, including the acquisition of K.F. Cambodia and PathoQuest, aimed at enhancing operational efficiency and securing supply chains [8][9] - The company plans to continue evaluating additional M&A opportunities to support clients in drug development [9][10] - The emphasis on NAMs (new approach methodologies) and AI as enabling technologies is part of the long-term strategy to enhance scientific capabilities [10][66] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding favorable DSA demand trends continuing into 2026, anticipating a return to organic revenue growth in the second half of the year [6][30] - The company expects operating margin improvement driven by the acquisition of K.F. Cambodia, with projected non-GAAP earnings per share growth of approximately 4%-9% for 2026 [28][32] - Management acknowledged challenges in the first quarter of 2026, including higher NHP sourcing costs and stock compensation expenses due to the CEO transition [43][44] Other Important Information - The company plans to generate at least $100 million in incremental cost savings in 2026, building on previous restructuring initiatives [33] - The anticipated decrease in the non-GAAP tax rate for 2026 is expected to be in the range of 22%-23% [46] - The company is focused on maintaining a disciplined approach to capital deployment, with a projected free cash flow of $375 million-$400 million for 2026 [48][49] Q&A Session Summary Question: Dynamics between RMS and DSA regarding NHPs - Management clarified that RMS is facing headwinds from lower NHP volumes due to timing, while DSA is experiencing higher sourcing costs due to increased demand for NHP studies [54][55] Question: DSA cancellations and their impact - Management indicated that cancellations and slippage are normal elements of the business, with current levels consistent with expectations and manageable due to a strong backlog [74][75]

Charles River Laboratories 4Q 2025 Results & 2026 Guidance February 18, 2026 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends o ...

Core Insights - VivoSim Labs has appointed JCBio for Korea and Tekon Biotech for China to distribute its NAMKind™ toxicology services, enhancing its commercial presence in the Asia-Pacific region [1][12] - The demand for human-relevant toxicology is increasing as drug developers seek faster and more reliable preclinical safety assessments [2][11] Distribution Agreements - JCBio will facilitate the deployment of NAMKind™ services in Korea, providing local coordination and scientific engagement to streamline evaluations [9][8] - Tekon Biotech aims to introduce VivoSim's NAMKind™ platforms to the Greater China market, addressing the need for accurate preclinical safety data [4][5] Market Dynamics - The in-vitro toxicology testing market in China is projected to grow from approximately $1.05 billion in 2023 to $2.26 billion by 2030, driven by increased R&D investment and evolving regulatory standards [5] - The pharmaceutical industry in China is shifting from generic manufacturing to innovative drug development, increasing the demand for predictive tools to mitigate late-stage clinical failures [7] Regulatory Alignment - Korea's regulatory body, MFDS, is aligning with the U.S. FDA's momentum towards adopting NAM-based evidence, which is expected to accelerate the acceptance of new toxicology techniques [3] Technological Advantages - VivoSim's NAMKind™ platform offers a modern approach to toxicology, designed to save time, reduce risk, and cut costs by providing human-based screening insights [10][12] - The platform is capable of delivering actionable results with a targeted 30-day turnaround time per compound, making it practical for both small and large molecules [12]